Why Novavax’s COVID Vaccine Results Were So Stellar

1 min read

Novavax (NASDAQ: NVAX) lags behind bigger players in the COVID-19 vaccine arena such as Pfizer and Moderna. However, in late January the biotech announced very promising results from a late-stage study of its experimental coronavirus vaccine. In this Motley Fool Live video recorded on Feb. 1, “The Wrap” host Jason Hall and Fool.com writer Keith Speights discuss why Novavax’s COVID-19 vaccine results were so stellar.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

3 Things to Watch in the Stock Market This Week

Next Story

Madison Square Garden Entertainment Corp. (MSGE) Q2 2021 Earnings Call Transcript

Latest from Blog